Skip to main content

Neuroblastoma Treatment Market is Increasing at a Healthy CAGR of 3.7% During Forecast to 2023


Market Highlights:
The global neuroblastoma is anticipated to hold a market value of 2.60 billion in 2017 and is expected to grow at a CAGR of 3.7% during the forecast period. Neuroblastoma is a childhood cancer most commonly occurs in children below the age of 5 years. The neuroblast may cause due to the immature cell growth or mutation in the gene responsible for controlling cell proliferation. The increasing cases of childhood cancer, rising research on neuroblastoma treatment and increasing spending on cancer treatment is expected to drive market growth over the forecast period. According to the American Society of Clinical Oncology (ASCO) April 2018 publication, every year, more than 700 children get diagnosed with neuroblastoma in the US and it is also indicated that neuroblastoma is the most common cancer in children younger than 1 year. It is more commonly found in boys compare to girls. The increasing cases of childhood cancer boost market growth during the forecast period.
Despite the drivers, shortage of trained healthcare specialists and the high cost of this therapy can restrain the Neuroblastoma Market growth over the assessment period.

Key Players:
United Therapeutics Corp., APEIRON Biologics AG, LUMITOS AG, NANTGE Healthcare, Pfizer Inc., GL Pharm Tech Corporation, Aetna Inc, RxStrategies, Inc
Segmentation:
·         The global neuroblastoma market has been segmented into diagnostics, treatment, and end user.
·         The market, on the basis of diagnostics, has been segmented into various tests, MIBG scan, imaging, and biopsy. The tests are further sub-segmented into bone marrow, tissue, urine, and blood.
·         The market, by treatment, has been segmented into surgery, chemotherapy, radiation therapy, stem cell transplant, immunotherapy, and monoclonal antibody treatment.
·         On the basis of end user, the global neuroblastoma market has been segmented into hospitals ambulatory surgical centers, diagnostic centers, research centers, and others.
Regional Analysis:
Geographically, the Americas is expected to dominate the global neuroblastoma market owing to the presence of well-developed healthcare sector, rising prevalence of infant cancer cases, and growing expenditure for the healthcare sector. Europe is expected to hold the second largest position in the global neuroblastoma market owing to the growing number of child healthcare centers for cancer treatment and raising awareness about the treatment for neuroblastoma.  According to the Cancer Research UK May 2018 publication, around 100 infants are detected with neuroblastoma every year in the UK. This provides favorable backgrounds for the neuroblastoma market to grow.
Asia-Pacific is expected to be the fastest growing market owing to the increasing children cancer base and increasing developments in the healthcare segment.
According to the Neuroblastoma Australia organization October 2018 article, every year approximately 40 cases of neuroblastoma are indicated in Australia due to some unknown genetic problems which will support the market growth.
Furthermore, the Middle Eastern and African region is expected to account for the least market share in the global market.

Comments

Popular posts from this blog

Covid 19 Analysis on Respiratory Therapeutic Devices Market Analysis and Forecast to 2023

Market Overview: The Global Respiratory Therapeutic Devices Market is predicted to scale to new heights and expand at a CAGR of 10.8% over the forecast period of 2017-2023, asserts Market Research Future (MRFR) in an in-depth study.                   The growth of the Global Covid 19 Analysis on Respiratory Therapeutic Devices Market Analysis   is primarily led by the recent surge in the incidence of chronic respiratory diseases such as asthma, COPD, and sleep disorder breathing. As per the estimates of the World Health Organization (WHO), approximately 235 Mn people suffered from asthma in 2017 across the globe. The growing burden of chronic respiratory diseases (CRDs) induces strong demand for respiratory therapeutic devices within the market. Moreover, with the increase in the global aging population, there is a greater need for respiratory therapeutic devices.     ...

Antibody Drug Conjugate Market is Presumed to Grow at a Reliable CAGR of 19% During Forecast to 2023

Antibody Drug Conjugate Market Analysis: Various factors are adding to the global antibody drug conjugate market share. These factors, as per the new MRFR report, include advances in medical technology, rising cases of cancer, growing obese population, and increasing aging population. Additional factors adding market growth include increasing collaborations between biotechnology companies, biopharmaceuticals, and research institutes, rising R&D on oncology diseases, increasing research on advanced drug discoveries, rising number of research on antibody therapies, and preclinical research. The global Antibody Drug Conjugate Market Share is likely to grow at a 19% CAGR between 2017- 2023 , reveals the new Market Research Future (MRFR) report. Antibody drug conjugates are new-age therapeutic agents that have three parts- a chemical linker to attach cytotoxic agents to antibodies, cytotoxic agents for killing target cancer cells, and specific antibodies for binding. Lymphoma, mult...

Desalting and Buffer Exchange Market is Growing at a Healthy CAGR of 10.5% During Forecast to 2023

Market Highlights: The Global Desalting and Buffer Exchange Market is anticipated to have held a market value of USD 615.20 million in the year 2017 and is expected to grow at a CAGR of 10.5% during the forecast period. Desalting and buffer exchange play a key role in biotechnological companies. Buffer exchange is used to place a protein solution into a more suitable buffer before applications such as electrophoresis, ion exchange, affinity chromatography among others. Get a Free Sample @ https://www.marketresearchfuture.com/sample_request/6633 Buffer exchange is the term used when one set of buffer salts in a sample is exchanged by another more appropriate buffer set. The rising demand for monoclonal antibodies, growing research and development expenditure by the biopharmaceutical companies, and rising focus on proteomic and genomic research is anticipated to boost the growth of the market over the forecast period. However, the dearth of skilled professionals is excepted to ...